Evidence map›Paper›PMID 33895922›Full record

ArticleDoklady. Biochemistry and biophysics2021

Differentiation of IMR32 Neuroblastoma Is Accompanied by a Global Change in the Transcriptome.

A G Stepchenko, T N Portseva, Yu V Ilyin, S G Georgieva, E V Pankratova

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

A G StepchenkoEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
T N PortsevaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
Yu V IlyinEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
S G GeorgievaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
E V PankratovaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia. panliz@mail.ru.
Engelhardt Institute of Molecular Biology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma is one of the most common cancers in infants and is often multidrug-resistant. One of the methods of treating neuroblastomas is to create conditions for their differentiation. In this work, we performed a full-transcriptome analysis of gene expression in an undifferentiated and differentiated in vitro human neuroblastoma cell line IMR-32 and identified the signaling pathways and biological processes that undergo the greatest changes during differentiation. The results obtained show that a complex heterogeneous population of nerve cells is formed at different stages of differentiation. In the cell population of differentiating neuroblastoma, the expression of genes in which cortical neuronal progenitor cells are enriched increases; at the same time, there are cells expressing markers of early postmitotic neurons. Cells differentiate in several different directions according to the type of synaptic mediator. At the same time, the differentiation of IMR-32 cells is accompanied by an increase in the transcription of genes that suppress the differentiation of nerve cells, Sox2 and PROM1, the expression of which is normally suppressed during in vivo differentiation.

Indexed as

TranscriptomeCell CommunicationCell DifferentiationDiagnosis, DifferentialHumansNeuroblastomaSignal TransductionTranscription, Geneticdifferentiationfull transcriptome analysisneuroblastoma

Identifiers

PMID33895922
OpenAlexW3159552188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.